It was very clear to us in January. We informed them that we would see our production reduced. The first decision we wanted to make was to remove from our production schedule less medically necessary products, like ointments, ophthalmics, suppositories. Thereafter, it was very important for us to focus all available production on medically necessary products.
Just to reassure people, because I know many things have been said in the newspapers about the current supply, we are currently supplying and meeting over 80% of the Canadian demand on our products.
If I take the top six most medically necessary products as identified by the key hospitals and Health Canada, and I'd like to name them if I can—morphine, midazolam, fentanyl, hydromorphone, naloxone, and dexamethasone—these are very critical products for hospitals, and today we are meeting over 95% of the demand.
When you look at managing a warning letter, mitigating the risk to patients, we've taken very seriously working with all the various stakeholders—hospital members, distributors—to create an allocation system that would minimize the shortage.
We understand it's a very difficult situation, but in light of all of this, I think we're working tirelessly to ensure a safe supply.